Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Multiple Myeloma 4Lymphoma, Large B-Cell, Diffuse 3Lymphoma, B-Cell, Marginal Zone 2Carcinoma, Non-Small-Cell Lung 2Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lung Neoplasms 1Locally Recurrent Skin Squamous Cell Carcinoma 1Leukemia, Plasma Cell 1Endometrial Neoplasms 1Clear-cell metastatic renal cell carcinoma 1Classic Follicular Lymphoma 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 91Blood Specimen Collection 44Cyclophosphamide 37Nivolumab 36Bevacizumab 36Standard of Care 32Carboplatin 31Surveys and Questionnaires 29Paclitaxel 28atezolizumab 25Exercise 25Pemetrexed 24Gemcitabine 24Cisplatin 23Fluorouracil 22Radiotherapy 20Leucovorin 20Dexamethasone 20Oxaliplatin 19Docetaxel 19Rituximab 16Irinotecan 16Cetuximab 16dostarlimab 15Drug Therapy 15Doxorubicin 15Biopsy 15130-nm albumin-bound paclitaxel 15Prednisone 14Ipilimumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × Hyaluronoglucosaminidase × 1 year × Clear all
NCT05256225 2026-06-03

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

National Cancer Institute (NCI)

Phase 3 Recruiting
360 enrolled
Gynecologic

Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡